Licensing status

Publication and contact information


Head and neck cancer

ADAM17; microRNA-145 (miR-145); SRY (sex determining region Y)-box 9 (SOX9); IL-6

Mouse and cell culture studies suggest increasing miR-145 expression could be useful for treating head and neck squamous cell carcinomas. In mice grafted with head and neck cancer-derived tumor-initiating cells, overexpression of miR-145 inhibited tumor growth and increased survival compared with a control vector. In head and neck cancer cell lines and mouse models, miR-145 blocked tumor initiation by inhibiting SOX9, ADAM17 and IL-6 signaling. Next steps include evaluating the effects of disrupting miR-145-regulated targets.

SciBX 6(15); doi:10.1038/scibx.2013.360
Published online April 18, 2013

Patent application filed; not yet available for licensing

Yu, C.-C. et al. Cancer Res.; published online April 2, 2013;
Contact: Shih-Hwa Chiou, Taipei Veterans General Hospital,
Taipei, Taiwan